Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] Group 1: Market Expansion and Challenges - Chinese pharmaceutical companies are shifting their export focus from raw materials and intermediates to innovative drugs, high-end formulations, and high-performance medical devices [2] - In the first eleven months of last year, China's pharmaceutical export value reached $100.895 billion, showing steady growth, but companies face increasing risks and challenges due to rising unilateralism and protectionism [2] - The Chinese government is encouraging regions to explore building trading platforms aimed at Southeast Asia, Central Asia, and other countries to enhance international promotion and allow more nations to benefit from China's pharmaceutical industry [2] Group 2: Cross-Border Initiatives - The China-ASEAN cross-border pharmaceutical procurement platform has successfully facilitated multiple cross-border transactions, including significant orders for domestic medical devices [3] - The China-Central Asia "Central Pharmacy" initiative has attracted innovative pharmaceutical and medical device companies to showcase over 2,200 medical devices, addressing the rigid demands of Central Asian countries [3] Group 3: Pricing Mechanisms and Support - The first overseas price registration certificate for a domestic drug treating infant vascular tumors has been issued, providing a crucial basis for companies to establish reasonable pricing in international markets [4] - The National Medical Insurance Administration is developing an international pharmaceutical pricing system that allows companies to set prices based on global market conditions rather than solely on domestic insurance payment prices [5] - A new pricing mechanism for newly launched drugs will be implemented to ensure that high-investment, high-risk innovative drugs have stable prices during their initial market entry, enhancing accessibility for quality products [5]

国家医保局召开医保药品器械（集采）交易与价格平台支持中国药械"走出去"座谈交流 2026年1月17日，国家医疗保障局在北京召开医保药品器械（集采）交易与价格平台支持中国药械"走出 去"座谈交流活动。来自国家部委、国际组织驻华机构、金融机构、药品器械（集采）交易与价格平 台、药械企业、新闻媒体的代表400余人参加，围绕如何更好发挥好医保药品器械（集采）交易与价格 平台功能，构建"走出去"政策和服务支持体系，开展深入交流。有关部委代表介绍了支持中国药品器械 的政策措施，金融机构代表介绍了针对中国药械企业的全周期金融服务方案，药械企业代表分享了海外 市场拓展与实践经验，并对平台建设提出了建设性意见。 动现场图） （交流活 上海联影医疗科技股份 嗨狠公司副总裁孙伟森 国家医保局全力部署支持中国药械"走出去"战略，将"依托各集采交易平台区域优势，形成医疗保障国 际药械采购创新模式，发挥好中国药品价格登记系统多元价格发现功能，提升中国医药产业的国际化水 平"列为2026年度重点工作。积极推动广西、新疆、天津、浙江宁波等医保药品器械（集采）交易平台 特色化、差异化发展，面向东南亚、中亚、其他共建"一带一路"国家等，搭建药械 ...